Brimica Genuair: Uses, Dosage & Side Effects

What Is Brimica Genuair and What Is It Used For?

Brimica Genuair is a fixed-dose combination inhaler that brings together two bronchodilator medicines with complementary mechanisms of action. The first active ingredient, aclidinium bromide (340 micrograms per dose), belongs to the class of long-acting muscarinic antagonists (LAMAs), sometimes also referred to as long-acting anticholinergics. The second active ingredient, formoterol fumarate dihydrate (12 micrograms per dose), is a long-acting beta-2 adrenergic agonist (LABA). Both substances act on the smooth muscle surrounding the airways in the lungs, but through different receptor pathways, and their combined effect results in greater and more sustained bronchodilation than either component can achieve alone.

In the airways of healthy individuals, the smooth muscle surrounding the bronchi and bronchioles remains relatively relaxed, allowing air to flow freely in and out of the lungs. In people with COPD, however, several pathological processes conspire to narrow these airways. Chronic inflammation leads to thickening of the airway walls, excessive mucus production clogs the air passages, and the smooth muscle around the airways contracts more readily and more forcefully than normal. This airway narrowing (bronchoconstriction) is the primary cause of the breathlessness, wheezing, and exercise limitation that characterize COPD.

Aclidinium bromide works by blocking the muscarinic M3 receptors on airway smooth muscle cells. Under normal conditions, the neurotransmitter acetylcholine, released from parasympathetic (vagal) nerve endings, binds to these M3 receptors and triggers smooth muscle contraction. In COPD, there is increased cholinergic (vagal) tone, meaning the parasympathetic nervous system is overactive and contributes to excessive bronchoconstriction. By blocking the M3 receptor, aclidinium prevents acetylcholine from causing muscle contraction, thereby relaxing the airways and reducing bronchoconstriction. Aclidinium has a notable pharmacological advantage: it is rapidly hydrolyzed in plasma to inactive metabolites, which means it has very low systemic exposure and a favorable anticholinergic side effect profile compared to some other LAMAs.

Formoterol fumarate, on the other hand, acts through an entirely different pathway. It stimulates beta-2 adrenergic receptors on airway smooth muscle cells. Activation of these receptors triggers an intracellular cascade involving cyclic adenosine monophosphate (cAMP) that leads to relaxation of the smooth muscle. Formoterol is notable among LABAs for its rapid onset of action — bronchodilation begins within 5 minutes of inhalation, similar to a short-acting reliever inhaler, yet its effects persist for at least 12 hours. This combination of rapid onset and long duration makes formoterol a particularly versatile bronchodilator.

The rationale for combining a LAMA and a LABA in a single inhaler is based on strong scientific and clinical evidence. Because the two drugs work through different and complementary mechanisms, their bronchodilatory effects are additive. The GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2024 report recommends LAMA/LABA combination therapy as the preferred initial pharmacological treatment for patients with COPD who have persistent symptoms despite monotherapy, or for patients with a high symptom burden (GOLD Group B and Group E). The combination approach targets both the cholinergic and adrenergic pathways simultaneously, providing more complete and sustained bronchodilation than either agent alone.

Brimica Genuair was evaluated in several large, randomized, double-blind, placebo-controlled clinical trials. The two pivotal studies were the ACLIFORM trial and the AUGMENT trial:

• ACLIFORM (ACLIdinium/FORMoterol): This multinational phase III trial enrolled 1,729 patients with moderate to severe COPD. Patients receiving aclidinium/formoterol 340/12 mcg twice daily demonstrated significantly greater improvements in trough FEV1 (forced expiratory volume in 1 second) at week 24 compared with placebo, aclidinium alone, and formoterol alone. The combination also provided significant improvements in peak FEV1 from 5 minutes post-dose, confirming the rapid onset of bronchodilation contributed by formoterol.
• AUGMENT: This trial enrolled 1,692 patients with moderate to severe COPD and confirmed the efficacy findings of ACLIFORM. The aclidinium/formoterol combination significantly improved trough FEV1, dyspnea (breathlessness), and health-related quality of life (as measured by the St George's Respiratory Questionnaire) compared with placebo and the individual monotherapies.

Both trials demonstrated that the combination was well tolerated, with the incidence and type of adverse events comparable to the individual components. Long-term extension studies have confirmed sustained efficacy and safety over 52 weeks of treatment. Pooled analyses have also shown that Brimica Genuair reduces the rate of moderate and severe COPD exacerbations compared to placebo, an important benefit given that exacerbations are associated with accelerated lung function decline, reduced quality of life, and increased mortality.

Brimica Genuair is approved by the European Medicines Agency (EMA) and is marketed in the European Union and several other countries. In some markets, the identical product is sold under the brand name Duaklir Genuair. The medication was first authorized in the EU in November 2014 and has since become a well-established treatment option for COPD maintenance therapy. It is important to note that Brimica Genuair is not indicated for the treatment of asthma and should not be used as a rescue inhaler for acute bronchospasm episodes.

What Should You Know Before Taking Brimica Genuair?

Contraindications

Brimica Genuair is contraindicated in patients with known hypersensitivity to aclidinium bromide, formoterol fumarate dihydrate, or any of the excipients. The excipients include lactose monohydrate (which contains small amounts of milk proteins). If you have a known allergy to any of these substances, including a severe allergy to milk proteins, you must not use this inhaler. Allergic reactions including rash, urticaria, angioedema, and bronchospasm have been reported with the individual components.

Although rare, paradoxical bronchospasm has been reported with inhaled bronchodilators, including formoterol. If you experience sudden worsening of wheezing, chest tightness, or shortness of breath immediately after using Brimica Genuair, stop using the inhaler and seek medical attention immediately. Paradoxical bronchospasm is a potentially life-threatening reaction that requires alternative therapy.

Warnings and Precautions

Before starting Brimica Genuair, inform your healthcare provider about any of the following conditions, as special precautions or monitoring may be necessary:

• Cardiovascular disorders: Use with caution in patients with coronary artery disease, cardiac arrhythmias (especially atrial fibrillation or flutter), idiopathic hypertrophic subaortic stenosis, hypertrophic obstructive cardiomyopathy, severe heart failure, or prolongation of the QTc interval. Formoterol, like other beta-2 agonists, can cause dose-related increases in heart rate, palpitations, and potentially ECG changes including QTc prolongation and ST-segment depression.
• Hypertension: Beta-2 agonists may cause elevated blood pressure in some patients. Monitor blood pressure regularly, especially during the initial phase of treatment.
• Convulsive disorders: Formoterol may exacerbate seizure activity in patients with epilepsy or other convulsive disorders. Use with caution and under close medical supervision.
• Thyrotoxicosis: Beta-2 agonists can worsen symptoms of hyperthyroidism. Inform your doctor if you have an overactive thyroid gland.
• Diabetes mellitus: Formoterol may cause elevations in blood glucose levels. Patients with diabetes should monitor their blood sugar more frequently when starting Brimica Genuair.
• Hypokalaemia: Beta-2 agonists can cause potentially serious hypokalaemia (low potassium levels). This effect may be potentiated by concomitant use of xanthine derivatives (e.g., theophylline), corticosteroids, or diuretics. Potassium levels should be monitored in patients at risk.
• Narrow-angle glaucoma: Aclidinium, as an anticholinergic agent, should be used with caution in patients with narrow-angle glaucoma. Seek medical advice immediately if you experience eye pain, blurred vision, visual halos, or colored images.
• Prostatic hyperplasia or bladder-neck obstruction: Anticholinergic medications can worsen urinary retention. If you have difficulty urinating or an enlarged prostate, inform your doctor before starting treatment.
• Severe hepatic impairment: No studies have been conducted in patients with severe hepatic impairment. Use with caution in this population.
• Severe renal impairment: Although no dose adjustment is necessary for mild to moderate renal impairment, limited data are available for patients with severe renal impairment.

Pregnancy and Breastfeeding

If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using Brimica Genuair. There are no adequate and well-controlled studies of aclidinium/formoterol in pregnant women. Animal reproduction studies with aclidinium did not reveal teratogenic effects, but formoterol has been shown to cause delayed ossification and reduced fetal weight in rats at very high doses. As a precaution, Brimica Genuair should be avoided during pregnancy unless the expected benefit to the mother outweighs the potential risk to the fetus.

Formoterol is known to inhibit uterine contractions due to its beta-2 agonist activity. Therefore, particular caution should be exercised during late pregnancy and labor. The use of Brimica Genuair during labor should only be considered if the expected benefit justifies the potential risk of inhibiting uterine contractions.

It is unknown whether aclidinium bromide or formoterol fumarate and their metabolites are excreted in human breast milk. In animal studies, aclidinium and its metabolites were detected in the milk of lactating rats. Because many drugs are excreted in human milk, a decision should be made whether to discontinue breastfeeding or to discontinue treatment, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.

Children and Adolescents

Brimica Genuair is not recommended for use in children and adolescents under 18 years of age. COPD does not typically occur in this age group, and no clinical data on the use of aclidinium/formoterol in pediatric patients are available. There is no relevant use of Brimica Genuair in the pediatric population for the approved indication.

Driving and Operating Machinery

Brimica Genuair has no or negligible influence on the ability to drive and use machines. However, dizziness and blurred vision have been reported uncommonly as side effects. If you experience these symptoms, refrain from driving or operating machinery until they have resolved.

How Does Brimica Genuair Interact with Other Drugs?

The drug interaction profile of Brimica Genuair is primarily pharmacodynamic rather than pharmacokinetic. Aclidinium bromide is rapidly hydrolyzed in plasma by chemical (non-enzymatic) and esterase-mediated hydrolysis, so it does not interact with cytochrome P450 enzymes. Formoterol is metabolized primarily through direct glucuronidation and O-demethylation via CYP2D6, CYP2C19, CYP2C9, and CYP2A6. However, at therapeutic inhaled doses, systemic levels of formoterol are very low, making clinically significant pharmacokinetic interactions unlikely.

The most important drug interactions to be aware of are pharmacodynamic interactions — situations where co-administered drugs may enhance or counteract the therapeutic or adverse effects of aclidinium and formoterol. The table below summarizes the key interactions:

Major Interactions

The most clinically significant interactions involve concomitant use with other long-acting anticholinergic or long-acting beta-2 agonist medications. Using Brimica Genuair alongside another LAMA (such as tiotropium or umeclidinium) or another LABA (such as salmeterol or indacaterol) would result in unnecessary duplication of the pharmacological class, increasing the risk of anticholinergic or adrenergic side effects without proportional additional benefit. This is why dual bronchodilator combination inhalers like Brimica Genuair are designed to replace the need for separate LAMA and LABA inhalers.

Non-selective beta-adrenergic blockers (such as propranolol or carvedilol) should be avoided in patients using Brimica Genuair, as they can directly antagonize the bronchodilatory effect of formoterol and may precipitate severe bronchospasm, which can be life-threatening in patients with COPD. If beta-blocker therapy is medically necessary (for example, for heart failure or post-myocardial infarction), cardioselective beta-1 blockers (such as bisoprolol or metoprolol) are preferred, though they should still be used with caution and at the lowest effective dose.

Minor Interactions

Inhaled corticosteroids (ICS), such as budesonide or fluticasone, can be safely used alongside Brimica Genuair. In fact, the GOLD 2024 guidelines recommend adding an ICS to LAMA/LABA therapy in patients with a history of frequent exacerbations and blood eosinophil counts above 300 cells per microlitre. Short-acting beta-2 agonists (SABAs) such as salbutamol may continue to be used as rescue medication for acute symptom relief while on Brimica Genuair, but increased use of SABAs may indicate inadequate disease control and should prompt a medical review.

Antidepressant medications, including selective serotonin reuptake inhibitors (SSRIs), do not have clinically significant interactions with Brimica Genuair and can be used concomitantly. Similarly, proton pump inhibitors, statins, and most common medications for hypertension (other than beta-blockers) do not interact with the components of Brimica Genuair.

What Is the Correct Dosage of Brimica Genuair?

Adults

The recommended and maximum dose is one inhalation twice daily. Patients should be instructed to take their doses at approximately the same times each day, ideally once in the morning and once in the evening, approximately 12 hours apart. This twice-daily regimen ensures consistent bronchodilation throughout the day and night. There is no evidence that increasing the dose beyond one inhalation twice daily provides additional benefit, and doing so increases the risk of side effects.

If a dose is taken later than intended but within a few hours of the usual time, the patient should take it as soon as they remember and then continue with their regular schedule. The timing does not need to be exact, but patients should aim for approximately 12-hour intervals between doses.

Elderly

Elderly patients represent the majority of the COPD population, and Brimica Genuair has been extensively studied in patients aged 65 years and older. Pharmacokinetic analyses have not identified clinically meaningful differences in drug exposure in elderly patients compared with younger adults. The Genuair device has been specifically designed with features that benefit elderly patients, including a low to medium inspiratory flow resistance (meaning patients do not need to inhale very forcefully to receive the full dose), a large easy-to-press button, a color control window for confirmation of inhalation, and a built-in dose counter.

Children

Renal and Hepatic Impairment

No dose adjustment is required for patients with mild to moderate renal or hepatic impairment. Aclidinium is primarily cleared through non-enzymatic hydrolysis in the blood, which is not affected by renal or hepatic function. Formoterol, at the low systemic levels achieved with inhaled dosing, is unlikely to be affected by renal impairment. However, as there are limited data in patients with severe renal impairment (creatinine clearance <30 mL/min) or severe hepatic impairment (Child-Pugh C), Brimica Genuair should be used with caution in these patients.

How to Use the Genuair Inhaler

Correct inhaler technique is essential for effective treatment. Follow these steps for each dose:

1. Remove the protective cap by gently squeezing the arrows on each side and pulling the cap off. Check the dose counter to ensure doses remain.
2. Hold the inhaler horizontally with the mouthpiece facing toward you and the green button facing upward. Do not tilt the inhaler.
3. Press the colored button fully down and then release it. The control window will change from red to green, indicating the device is ready. Do not hold the button down while inhaling.
4. Breathe out gently away from the inhaler (never breathe out through the device).
5. Place the mouthpiece between your lips and breathe in strongly and deeply through the inhaler. You will hear a click, and the control window should change from green back to red, confirming successful inhalation.
6. Remove the inhaler from your mouth and hold your breath for as long as comfortable (ideally 5–10 seconds), then breathe out slowly through your nose.
7. Replace the protective cap immediately after use.

If the control window remains green after inhaling, this means the dose was not successfully inhaled. Close your lips tightly around the mouthpiece and try again with a strong, deep breath. If the window still does not change to red, the dose may have been released but not properly inhaled. Do not attempt to reload the device. Instead, take your next dose at the usual time.

Missed Dose

If you forget a dose, take it as soon as you remember unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and take the next dose at the usual time. Do not take a double dose to make up for a missed one. If you regularly forget your doses, speak to your doctor or pharmacist about strategies to help you remember, such as setting a reminder alarm.

Overdose

There is no specific antidote for Brimica Genuair overdose. Treatment is symptomatic and supportive. In cases of significant overdose, cardiac monitoring is advisable due to the potential for formoterol to cause cardiac arrhythmias and electrolyte imbalances. Potassium supplementation and correction of metabolic disturbances may be required. The use of cardioselective beta-blockers as an antidote for severe formoterol toxicity should be considered with extreme caution, as beta-blockade can precipitate bronchospasm in COPD patients.

What Are the Side Effects of Brimica Genuair?

Like all medicines, Brimica Genuair can cause side effects, although not everybody gets them. The safety profile of Brimica Genuair is well-characterized from clinical trials involving thousands of COPD patients and from extensive post-marketing surveillance. The side effects reflect the combined pharmacological properties of both active ingredients: anticholinergic effects from aclidinium (such as dry mouth) and adrenergic effects from formoterol (such as tremor and palpitations).

The following side effect frequency grid categorizes adverse reactions according to the standard frequency classifications used by the European Medicines Agency:

The majority of side effects observed in clinical trials were mild to moderate in severity and transient in nature. Headache was the most frequently reported adverse event in both the treatment and placebo groups. Nasopharyngitis and cough are common in the COPD population regardless of treatment. Oral candidiasis can be minimized by rinsing the mouth with water after each inhalation, although its incidence with Brimica Genuair is lower than with inhaled corticosteroid-containing regimens.

Cardiovascular side effects, particularly tachycardia and palpitations, are related to the beta-2 agonist activity of formoterol. These effects are generally dose-related and are uncommon at the recommended therapeutic dose. In clinical trials, the incidence of serious cardiovascular adverse events was comparable between the Brimica Genuair and placebo groups. However, patients with pre-existing cardiovascular conditions should be monitored during the initiation of therapy.

Anticholinergic side effects such as dry mouth, urinary retention, and blurred vision are related to the aclidinium component. These effects are less common with aclidinium than with some other LAMAs (such as tiotropium), partly because aclidinium is rapidly metabolized to inactive products in the circulation, resulting in lower systemic anticholinergic exposure.

If you experience any persistent or troublesome side effects, or any new symptoms not listed above, report them to your healthcare provider. You can also report suspected side effects to your national pharmacovigilance authority (e.g., the Medicines and Healthcare products Regulatory Agency in the UK, or the relevant agency in your country). Reporting helps gather important information about the safety of this medicine.

How Should You Store Brimica Genuair?

Proper storage of Brimica Genuair is important to maintain the quality, stability, and efficacy of the medicine. The inhalation powder is sensitive to moisture, and incorrect storage can affect the consistency and deliverability of each dose. Follow these storage guidelines carefully:

• Temperature: Store at or below 25°C (77°F). Brief excursions up to 30°C are acceptable, but prolonged exposure to heat can affect the powder formulation.
• Sealed pouch: Keep the inhaler in its original sealed foil pouch until you are ready to begin using it. The pouch contains a desiccant (moisture absorber) to protect the powder from humidity during storage.
• After opening: Once removed from the sealed pouch, the inhaler must be used within 60 days, regardless of how many doses remain. Write the date you opened the pouch on the inhaler label to help you track this.
• Moisture: Keep the inhaler dry. Do not store it in the bathroom or other humid environments. Always replace the protective cap immediately after use to prevent moisture from entering the device.
• Do not freeze: Freezing temperatures can damage both the medicine and the inhaler device mechanism.
• Keep out of reach of children: Store the inhaler in a safe place where children cannot access it.
• Disposal: Discard the inhaler when the dose indicator reaches zero (showing a red band in the dose counter window), or after 60 days from opening the pouch, whichever occurs first. Do not attempt to open or dismantle the device. Dispose of in accordance with local requirements for pharmaceutical waste.

Do not use Brimica Genuair after the expiry date stated on the carton, pouch, and inhaler label. The expiry date refers to the last day of that month. If you notice that the powder in the inhaler looks unusual or the device is damaged, do not use it and consult your pharmacist for a replacement.

What Does Brimica Genuair Contain?

Brimica Genuair contains two active substances and one excipient:

Active Ingredients

• Aclidinium bromide: Each delivered dose contains 340 micrograms of aclidinium (equivalent to 396 micrograms of aclidinium bromide). Aclidinium bromide is a synthetic quaternary ammonium compound with the molecular formula C₂₆H₃₀BrNO₄S₂. It is a white to off-white powder. Aclidinium acts as a competitive, reversible antagonist at muscarinic M3 receptors in airway smooth muscle, providing long-acting bronchodilation. Its unique chemical structure makes it susceptible to rapid hydrolysis in human plasma, which accounts for its low systemic bioavailability and favorable anticholinergic side effect profile.
• Formoterol fumarate dihydrate: Each delivered dose contains 12 micrograms of formoterol fumarate dihydrate (equivalent to 11.8 micrograms of formoterol fumarate). Formoterol is a potent, selective, long-acting beta-2 adrenergic receptor agonist. It provides bronchodilation through stimulation of intracellular adenylate cyclase, increasing cAMP levels in airway smooth muscle cells, which leads to muscle relaxation. Formoterol has both a rapid onset (within 5 minutes) and a long duration of action (at least 12 hours).

Excipient

• Lactose monohydrate: This is the carrier substance that helps the active ingredients disperse properly during inhalation. Lactose monohydrate is a naturally occurring sugar derived from milk. It contains small amounts of milk proteins as a processing residue. Patients with severe lactose intolerance or known allergy to milk proteins should inform their doctor, although the amount of lactose delivered per inhalation is very small (approximately 10–12 mg) and is generally well tolerated even by patients with lactose intolerance.

The Genuair inhaler device itself is made from acrylonitrile butadiene styrene (ABS) polymer, polycarbonate, polyoxymethylene (POM), polybutylene terephthalate (PBT), and stainless steel spring components. These materials are inert and do not interact with the medication. The device contains approximately 60 metered doses and features a dose counter, a colored control window, and a protective cap.